Cocrystal Pharma, Inc. (COCP)

$0.4205

+0.01 (+1.33%)
Rating:
Recommendation:
Buy
Symbol COCP
Price $0.4205
Beta 0.800
Volume Avg. 0.26M
Market Cap 40.986M
Shares () -
52 Week Range 0.37-1.49
1y Target Est -
DCF Unlevered COCP DCF ->
DCF Levered COCP LDCF ->
ROE -15.11% Sell
ROA -15.89% Sell
Operating Margin -
Debt / Equity 2.44% Neutral
P/E -
P/B 0.56 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest COCP news


Dr. Gary Wilcox
Healthcare
Biotechnology
NASDAQ Capital Market

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.